Patents for A61P 35 - Antineoplastic agents (221,099)
02/2006
02/08/2006EP1622569A2 Aza spiro alkane derivatives as inhibitors of metallproteases
02/08/2006EP1622563A2 Improved heat shock protein-based vaccines and immunotherapies
02/08/2006EP1478393A4 Anti-pathogen treatements
02/08/2006EP1453517B1 Platinum derivative pharmaceutical formulations
02/08/2006EP1358162B1 Dihydroindole and tetrahydroquinoline derivatives
02/08/2006EP1352052B1 Method for preparing submicron particle suspensions of pharmaceutical agents
02/08/2006EP1318978B1 N-acylsulfonamide apoptosis promoters
02/08/2006EP1297006B1 Regulation of human prostasin-like serine protease
02/08/2006EP1144348B1 Lta 4 hydrolase inhibitors
02/08/2006EP1119362B1 Use of tetracycline derivatives to enhance interleukin-10 production
02/08/2006EP1068297B1 Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
02/08/2006EP0812356B1 Prostate-specific membrane antigen and uses thereof
02/08/2006CN1732172A Epothilone derivatives
02/08/2006CN1732147A Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
02/08/2006CN1732016A Modified cytokines for use in cancer therapy
02/08/2006CN1732007A Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
02/08/2006CN1731989A A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
02/08/2006CN1731988A Sustained release pharmaceutical composition
02/08/2006CN1730665A PI3K enzyme inhibitor quick-speed screening method
02/08/2006CN1730658A Recombinant plasmid for curing prostate gland cancer and melanoma
02/08/2006CN1730493A Mouse single-chain antibody of anti- nasopharyngeal carcinoma and its DNA sequence
02/08/2006CN1730489A Muc1 and C end active fragment mutants, their encoding gene and use thereof
02/08/2006CN1730479A Aloe dihydro-coumarin and its separation method and uses
02/08/2006CN1730100A Anti-lymphadenoma gene family specificity nucleic acid vaccine combination
02/08/2006CN1730099A Immune isolated cell medicine, its preparing process and its application in killing tumours
02/08/2006CN1730093A Chinese traditional medicine preparation for treating cancer and application thereof
02/08/2006CN1730020A Method for preparing Chinese medicinal formulation for treating tumor
02/08/2006CN1730009A Novel drug administering route of ginseng stem and leave general saponin and its preparation process and new indications
02/08/2006CN1730003A Marsdenia tenacissima soft capsule and its preparation method
02/08/2006CN1729998A Cancer treating
02/08/2006CN1729990A Dripping pills of diosgenin and its preparation process
02/08/2006CN1240846C Immunity stimulus amlose of bacterial strain from linteus and its application
02/08/2006CN1240836C Transforming growth factor alpha HI
02/08/2006CN1240721C Conjugate of lidamycin, monoclonal antibody and its Fab'segment and its application in targeting treatment of colon cancer and other tumors
02/08/2006CN1240717C Low-toxicity human interferon-alpha analog
02/08/2006CN1240714C Chirality peptide antigen and vaccine composition based on core sequence of mucin 1
02/08/2006CN1240706C Process for producing super critical extracting caterpillar fungus deoxynucleoside
02/08/2006CN1240705C Chemotherapy medication-coupler of gem-bis phosphoric acid and synthetic method as well as usage
02/08/2006CN1240688C Quinazoline compounds
02/08/2006CN1240681C Nitrile derivatives as cathepsin K inhibitors
02/08/2006CN1240669C Phytosphingosine derivate with antitumor activity
02/08/2006CN1240439C Genetic switch medicine for treating tumor
02/08/2006CN1240437C Oral administered self-emulsifying formulations of pyranone proteinase inhibitors
02/08/2006CN1240428C Medicine for treating leukaemia
02/08/2006CN1240398C Application of active biologics prepared turtle and/or tortoise organs and animal penis in preparing medicine
02/08/2006CN1240390C Biologic converted ginseng composition and preparing process thereof
02/08/2006CN1240388C Selective estrogen receptor modulator in combination with dehydroepiandrosterone or its derivative
02/08/2006CN1240387C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
02/08/2006CN1240386C Matrix metal proteinase and tumor necrosis inhibitor
02/08/2006CN1240383C Sophoridine soft capsule for curing malignant tumor, its preparation method and purposes
02/08/2006CN1240382C Medicine combinations using pyridoindolone derivatives and anticancer agent as base
02/08/2006CN1240380C Phase transfer catalyzed glycosidation of an indolocarbazole
02/08/2006CN1240375C Preparation of low dosage medicinal composition with uniform distribution and effect
02/07/2006US6995272 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
02/07/2006US6995261 Treatment of meningitis, septic shock, infections, reperfusion injuries, hepatitis, pancreatitis; bone, autoimmune, viral, and respiratory system disorders; antiinflammatory, antiarthritic, and antitumor agents
02/07/2006US6995244 A mutant binding to prolactin receptor through site 1, does not bind through site 2 nor has diminished binding through site 2, and exhibits <1% of unmodified agonist activity; anticarcinogenic, -tumor and metastatis agents; breast/prostate cancer
02/07/2006US6995188 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
02/07/2006US6995184 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors
02/07/2006US6995175 Anticancer agents
02/07/2006US6995171 Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
02/07/2006US6995164 Methods of treating tumors
02/07/2006US6995162 Substituted alkylamine derivatives and methods of use
02/07/2006US6995154 Catalyst for joining, breaking of Dna; antitumor, anticancer agents
02/07/2006US6995151 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
02/07/2006US6995150 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
02/07/2006US6995144 for example, 6-[2-[4-(2-fluorophenoxymethyl)piperidino]ethyl]-1H-pyrazin-2-one; therapeutic or prophylactic agent for diabetic neuralgia, HIV neuralgia, postherpetic neuralgia, nerve system disorders
02/07/2006US6995135 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
02/07/2006US6995133 invention describes reduced synthesis of IFN alpha 5 in livers of patients with hepatitis C in comparison to healthy livers; demonstrates importance of use of such interferon sub-types in fabricating compositions for treating viral hepatopathies
02/07/2006US6994978 Human osteoclast derived cathepsin
02/07/2006US6994977 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex
02/07/2006US6994863 Pharmaceutical and cosmetic carrier and composition for topical application
02/07/2006US6994862 Comprising 9-90% by weight monoglyceride compound, 0.01-90% by weight emulsifier, 0-50% by weight water-insoluble material, 0-90.9% by weight of organic solvent; drug delivery
02/07/2006US6994857 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein
02/07/2006US6994853 administering to a cancer patient in a time-staggered manner: autologous or allogeneic tumor cells of the same tumor type each treated to prevent their survival after reinfusion; and intact bispecific and/or trispecific antibodies
02/07/2006US6994840 Kit for radiolabeling ligands with yttrium-90
02/07/2006US6994283 Method for pulverizing to fine powder
02/07/2006CA2340202C Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors
02/07/2006CA2273479C 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
02/07/2006CA2268484C Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
02/07/2006CA2262454C Purine inhibitors of cyclin dependent kinase 2 and ikb-.alpha.
02/07/2006CA2221075C Use of aminoalcohol derivatives in the treatment of liver disease
02/07/2006CA2173158C Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them
02/07/2006CA2137764C Pharmaceutical compositions comprising solutions or dispersions of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride
02/07/2006CA2026147C Cytotoxic agents comprising maytansinoids and their therapeutic use
02/02/2006WO2006012422A1 Imidazopyrazine as tyrosine kinase inhibitors
02/02/2006WO2006012374A1 Substituted aryl-amine derivatives and methods of use
02/02/2006WO2006012359A2 Methods for inducing the differentiation of blood monocytes into functional dendritic cells
02/02/2006WO2006011682A1 Method of preserving and transporting lymphocytes
02/02/2006WO2006011670A1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
02/02/2006WO2006010859A1 Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
02/02/2006WO2005123772A3 Anti-cancer therapy
02/02/2006WO2005107782A3 Use of a modulator of gene expression in the treatment of cancer
02/02/2006WO2005105833A3 Novel herpes simplex viruses and uses thereof
02/02/2006WO2005094899A8 Clusterin antisense therapy for treatment of cancer
02/02/2006WO2005001038A3 Recombinant anti-cd30 antibodies and uses thereof
02/02/2006WO2002094990A3 Receptors and membrane-associated proteins
02/02/2006US20060026700 Tissue specific genes and gene clusters
02/02/2006US20060025597 4-(Aminomethyl)-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione hydrochloride; cytokines level reduced; tumor necrosis factor inhibitors; nontoxic; anticarcinogenic agents; antitumor agents (solid/blood-borne); cardiovascular disorders; osteoporosis; antiinflammatory agents; autoimmune diseases
02/02/2006US20060025576 Multivalent antibodies and uses therefor
02/02/2006US20060025484 Use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea for treatment of pancreatic carcinomas, soft tissue sarcomas, testicular tumors, lymphomas, thymomas, wilms' tumors, renal carcinomas, melanomas, lung tumors, intracerebral metastases, tumors in the head and neck area and mammary carcinomas